Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

AIM: To evaluate the cardiovascular (CV) efficacy of liraglutide and semaglutide in patients with type 2 diabetes (T2D) and peripheral artery disease (PAD). MATERIALS AND METHODS: LEADER and SUSTAIN 6 trials investigated subcutaneous liraglutide (≤1.8 mg/day) and semaglutide (0.5 or 1.0 mg/week), re...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Al‐Omran, Mohammed, Leiter, Lawrence A., Mazer, C. David, Rasmussen, Søren, Saevereid, Hans A., Sejersten Ripa, Maria, Bonaca, Marc P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325529/
https://www.ncbi.nlm.nih.gov/pubmed/35332654
http://dx.doi.org/10.1111/dom.14700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325529/
https://www.ncbi.nlm.nih.gov/pubmed/35332654
http://dx.doi.org/10.1111/dom.14700

Ejemplares similares